FOA Title: 
Notice of Intent to Publish a Funding Opportunity Announcement for Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3)
Grant Type: 
Primary IC: 
Release Date: 
Apr 26 2018
Expiration Date: 
AC Source: 
Notice Intent Publish Funding Opportunity Announcement Rare Disease Cohorts Heart, Lung, Blood Sleep Disorders UG3/UH3) Notice Number: NOT-HL-18-624 Key Dates Release Date: April 26, 2018 Estimated Publication Date Funding Opportunity Announcement: 12/01/2018 First Estimated Application Due Date : 02/01/2019 Earliest Estimated Award Date:10/31/2019 Earliest Estimated Start Date: 12/31/2019 Related Announcements NOT-HL-18-620 Rescinded Issued National Heart, Lung, Blood Institute NHLBI) Purpose Notice updates supercedes replaces previous Notice Intent Publish NOT-HL-18-620. Notice provides clarification intended funding information. National Heart, Lung Blood Institute intends promote new initiative establish cohorts rare heart, lung, blood, and/or sleep HLBS) diseases enables multidisciplinary teams conduct natural history mechanistic studies provide evidence base future clinical trials improved diagnostics.  studies help advance fundamental insights key molecular, genomic, clinical, environmental behavioral determinants rare HLBS diseases their outcomes leading diagnostic therapeutic strategies.   NHLBI interested applications will address questions relevant the NHLBI mission, address gaps the NHLBI?s portfolio rare disease cohorts that align the Institute ' s Strategic Vision ). NHLBI intends to utilize UG3/UH3 activity code, bi-phasic, milestone-driven cooperative agreement. Details the planned FOA provided below. Notice being provided allow potential applicants sufficient time develop responsive proposals.  FOA expected be published October 2018 anticipated application receipt dates February 2019 February 2020. Notice rescinds replaces NOT-HL-18-620. Research Initiative Details planned initiative provide opportunities efficiently advance rare disease research using genetics deep phenotyping characterize disease to identify disease sub-types; use data science methods integrate clinical patient-reported outcomes PROs) laboratory, imaging omics data understand natural history disease;  generate data differentiate patients the same morphological phenotype different genetic mutations  severity outcomes; elucidate genotype-phenotype interactions multisystem phenotyping develop reliable valid predictive tools determine will respond which treatments when intervene; to encourage innovative methods such telemedicine reach subjects rare diseases located remote locations without access a major academic medical center. goal this initiative to encourage creative innovative research; such, applications should propose studies investigating hypotheses research questions currently addressed cohorts funding the NHLBI. RFA invite applications propose cohorts are created de novo  or re-establish study populations enrolling patients previously-funded cohorts, clinical trials registries. Although funding information yet be determined, a guidance NHLBI estimates the typical total funding per year the research described herein be to $1.5 million. 1.5 million per year an estimate a typical rare disease cohort a typical number candidate research subjects. However, for rare diseases are common from larger cohorts be assembled, expectation that budget submitted be appropriate the size the cohort would well justified the submission. Funding Information Estimated Total Funding TBD Expected Number Awards TBD Estimated Award Ceiling TBD Primary CFDA Numbers 93.837, 93.838, 93.839, 93.840, 93.233 Anticipated Eligible Organizations Public/State Controlled Institution Higher Education Private Institution Higher Education Nonprofit 501(c)(3) IRS Status than Institution Higher Education) Nonprofit without 501(c)(3) IRS Status than Institution Higher Education) Small Business For-Profit Organization than Small Business) State Government Indian/Native American Tribal Government Federally Recognized) County governments City township governments Special district governments Indian/Native American Tribally Designated Organization Native American tribal organizations than Federally recognized tribal governments) Indian/Native American Tribal Government than Federally Recognized) Regional Organization Applications not being solicited this time. Inquiries Please direct inquiries to: Ellen M. Werner, PhD, MA   National Heart, Lung, Blood Institute  301-435-0065